Vascepa Patent Status and Generic Entry
Vascepa (icosapent ethyl), made by Amarin, faces patent challenges that could affect long-term pricing, but its core patents expire in 2033, with some pediatric exclusivity extending to 2034.[1] No generics are approved yet, so branded Vascepa remains the main option, and current savings programs continue uninterrupted.[2]
Current Vascepa Savings Options Available
Patients can still access these:
- Vascepa Savings Card: Eligible commercially insured patients pay as little as $9 per month for up to 13 fills (48 months max), regardless of income. Apply at vascepa.com/savings.[3]
- Patient Assistance Program (HCP Connect): Uninsured or underinsured patients may get free Vascepa if income-qualified (up to 600% FPL). Contact 1-877-304-3188 or Amarin support.[4]
- GoodRx and Pharmacy Discounts: Coupons drop cash prices to $300-400/month at major chains like CVS or Walgreens, beating list prices over $1,000.[5]
These programs show no signs of discontinuation as of late 2024.
What Happens If Generics Launch
Generic entry (possible post-2026 if challenges succeed) would lower costs naturally, but branded savings cards often stay active to compete.[6] Amarin has kept programs running during past disputes, like the 2020 generic settlement delaying entry.[1] Patients on savings cards can typically switch to generics without losing eligibility for assistance.
Why Savings Might Change and Patient Risks
Amarin adjusts programs based on revenue—post-patent cliffs, discounts deepen to retain share against generics.[2] Risks include:
- Insurer shifts to generics, ending coverage for branded Vascepa.
- Program caps hitting sooner for heavy users.
Check vascepa.com or call 1-877-205-3326 for latest terms, as rules evolve with litigation (e.g., ongoing suits vs. Dr. Reddy's).[1]
[1]: DrugPatentWatch.com - Vascepa Patents
[2]: Amarin Investor Updates (Q3 2024)
[3]: Vascepa Savings Card
[4]: Amarin HCP Connect
[5]: GoodRx Pricing Data (October 2024)
[6]: FDA Orange Book - Vascepa Paragraph IV Challenges